文献速递肝病

衰弱变化与肝硬化患者等待名单死亡率相关

Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
PubMed 文献 · J Hepatol · 2020-03-30

本研究纳入美国8个中心的1093例等待肝移植的肝硬化门诊患者,纵向使用肝衰弱指数(LFI)评估衰弱变化。中位随访11个月,223例(20%)因病情死亡或退出等待名单。校正基线LFI、年龄、身高、MELD-Na和白蛋白后,每3个月LFI变化0.1单位与死亡/退出风险增加2.04倍相关(95%CI 1.35-3.09)。衰弱改善者死亡/退出风险更低。

要点

  • 肝硬化患者衰弱恶化与死亡/退出等待名单风险独立相关。
  • 每3个月LFI变化0.1单位,死亡/退出风险增加2.04倍(95%CI 1.35-3.09)。
  • 衰弱改善者死亡/退出风险更低,支持纵向监测衰弱。

核心结论

  • 衰弱恶化与肝硬化患者死亡/退出等待名单显著相关,独立于基线衰弱和MELD-Na。
  • 衰弱改善的患者死亡/退出等待名单风险更低。
  • 数据支持使用LFI对肝硬化患者进行纵向衰弱测量,并为逆转衰弱的干预研究奠定基础。

研究设计与样本

  • 多中心前瞻性队列研究,纳入美国8个中心等待肝移植的肝硬化门诊患者。
  • 共分析1093例患者的2851次访视,使用肝衰弱指数(LFI)进行动态衰弱测试。
  • 采用多水平线性混合效应回归建模预测每3个月LFI变化(ΔLFI),并按衰弱轨迹分类。
  • 采用竞争风险回归评估基线LFI和预测ΔLFI对死亡/退出等待名单的亚风险比(sHR),以移植为竞争风险。

主要发现

  • 中位随访11个月,223例(20%)因病情死亡或退出等待名单。
  • 衰弱严重恶化组基线LFI更差,更可能合并非酒精性脂肪性肝病、糖尿病或依赖透析。
  • 死亡/退出等待名单的累积发生率随ΔLFI恶化分组增加而升高。
  • 校正基线LFI、年龄、身高、MELD-Na和白蛋白后,每3个月ΔLFI变化0.1单位与死亡/退出风险增加2.04倍相关(95%CI 1.35-3.09)。

关键数值与推荐

  • 每3个月LFI变化0.1单位对应的死亡/退出等待名单亚风险比(sHR)为2.04(95%CI 1.35-3.09)。
  • 中位随访11个月,20%(223/1093)的患者死亡或退出等待名单。

临床怎么用

  • 对等待肝移植的肝硬化患者,应使用LFI进行纵向衰弱监测,而非仅依赖单次评估。
  • 衰弱恶化提示死亡/退出等待名单风险升高,需加强临床关注。
  • 衰弱改善与更低风险相关,支持开展逆转衰弱的干预措施。

局限性

  • 研究为观察性设计,无法确立衰弱变化与死亡/退出之间的因果关系。
  • 研究对象为等待肝移植的肝硬化门诊患者,结论外推至其他肝硬化人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: To date, studies evaluating the association between frailty and mortality in patients with cirrhosis have been limited to assessments of frailty at a single time point. We aimed to evaluate changes in frailty over time and their association with death/delisting in patients too sick for liver transplantation. METHODS: Adults with cirrhosis, listed for liver transplantation at 8 US centers, underwent ambulatory longitudinal frailty testing using the liver frailty index (LFI). We used multilevel linear mixed-effects regression to model and predict changes in LFI (ΔLFI) per 3 months, based on age, gender, model for end-stage liver disease (MELD)-Na, ascites, and hepatic encephalopathy, categorizing patients by frailty trajectories. Competing risk regression evaluated the subhazard ratio (sHR) of baseline LFI and predicted ΔLFI on death/delisting, with transplantation as the competing risk. RESULTS: We analyzed 2,851 visits from 1,093 outpatients with cirrhosis. Patients with severe worsening of frailty had worse baseline LFI and were more likely to have non-alcoholic fatty liver disease, diabetes, or dialysis-dependence. After a median follow-up of 11 months, 223 (20%) of the overall cohort died/were delisted because of sickness. The cumulative incidence of death/delisting increased by worsening ΔLFI group. In competing risk regression adjusted for baseline LFI, age, height, MELD-Na, and albumin, a 0.1 unit change in ΔLFI per 3 months was associated with a 2.04-fold increased risk of death/delisting (95% CI 1.35-3.09). CONCLUSION: Worsening frailty was significantly associated with death/delisting independent of baseline frailty and MELD-Na. Notably, patients who experienced improvements in frailty had a lower risk of death/delisting. Our data support the longitudinal measurement of frailty, using the LFI, in patients with cirrhosis and lay the foundation for interventional work aimed at reversing frailty. LAY SUMMARY: Frailty, as measured at a single time point, is predictive of death in patients with cirrhosis, but whether changes in frailty over time are associated with death is unknown. In a study of over 1,000 patients with cirrhosis who underwent frailty testing, we demonstrate that worsening frailty is strongly linked with mortality, regardless of baseline frailty and liver disease severity. Notably, patients who experienced improvements in frailty over time had a lower risk of death/delisting. Our data support the longitudinal measurement of frailty in patients with cirrhosis and lay the foundation for interventional work aimed at reversing frailty.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lai JC, Dodge JL, Kappus MR, et al. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J Hepatol. 2020. PMID: 32240717. doi:10.1016/j.jhep.2020.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。